

Immunohistochemical Staining of CD8 α in Diabetic Mouse Kidney

Ming-Zhi Zhang^{1,2,*} and Raymond C Harris^{1,2,3,*}

¹Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; ²Vanderbilt Center for Kidney Disease, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; ³Department of Veterans Affairs, Nashville, Tennessee, USA

*For correspondence: ray.harris@vanderbilt.edu; ming-zhi.zhang@vanderbilt.edu

[Abstract] Immune cell infiltration, particularly cytotoxic CD8 α lymphocyte infiltration, plays an important role in development of diabetic nephropathy. Although CD8 α infiltration can be evaluated by its production of cytokines, its localization in the kidney is of particular importance. The current protocol describes CD8 α immunostaining using a Vectastain ABC kit. This protocol works well with most commercially available antibodies, including CD8 α antibodies in kidneys of diabetic mice.

Keywords: Diabetic nephropathy, CD8 α lymphocyte, Immunostaining, ABC kit, Biotinylated secondary antibody

[Background] Diabetic nephropathy (DN), a complication of diabetes, is the most common cause of end-stage renal disease. Pathological changes in DN are closely correlated with the degree of renal immune cell infiltration, particularly toxic CD8 α lymphocyte infiltration. Therefore, a sensitive and reliable method to localize CD8 α lymphocytes in the kidney will facilitate the research in diabetic nephropathy as well as other fields relating inflammation (Li *et al.*, 2018).

Materials and Reagents

1. Syringe
2. Filter (Tisch Scientific, Millex, syringe-driven filter unit, 0.22 μ m)
3. Paraffin slides
4. Glass staining jar (IMEB, SKU:SD-09)
5. M.O.M Kit for detecting primary antibodies on mouse tissue (Vector Laboratories, Inc., catalog number: PK-2200)

Note: This Kit includes blocking solution and diluent for dilution of both primary and secondary antibodies (stored at 4 °C).

6. Biotinylated goat anti-mouse IgG antibody (Vector Laboratories, catalog number: BA-9200, stored at 4 °C)
7. Vectastain Elite ABC HRP Kit (Vector Laboratories, catalog number: PK-6101, stored at 4 °C)
8. Biotinylated goat anti-rat IgG antibody (Vector Laboratories, catalog number: BA-9400, stored at 4 °C)

9. Rat anti-mouse CD8α antibody [AbD Serotec (now Bio-Rad Laboratories), catalog number: MCA2694, stored at -20 °C]
10. Normal goat serum [Sigma-Aldrich (now Millipore, Sigma), catalog number: G9023-10ML, stored at -20 °C]
11. Toluidine blue O (Sigma-Aldrich, catalog number: T3260-5G)
12. 0.1 M Phosphate buffer (AlboChemicals, SKU: B0787MV4W2)
13. Xylene
14. Ethanol
15. Methanol
16. H₂O₂
17. PBS
18. Permount (Fisher Scientific, catalog number: SP15-100)
19. Tris-HCl
20. Blocking solution (see Recipes)
21. Counterstain stock solution (see Recipes)
22. Counterstain working solution (see Recipes)
23. DAB solution (see Recipes)

Equipment

1. Beakers (Nalgene, catalog number: 1542E06)
2. Orbit shaker (Labline, catalog number: 3520)
3. Regular light microscope (Wetzlar, Leitz Orthoplan)
4. Oven

Procedure

Note: In this protocol, the staining does not require antigen retrieval.

1. Choosing paraffin slides
 - a. If possible, choose appropriate slides (with intact tissue sections) with date (experiment) and number (block and slide).
 - b. Label slides with staining date, antibody and dilution, host species using pencil.
 - c. Place slides in glass staining jar, being careful not to scrape other slides/tissues.
Note: Be sure to record slide date, number, antibody, dilution information in staining book along with start times on small form.
2. Pre-treatment of slides
 - a. Deparaffinate: Soak slide in xylene: 2 x 15 min.
 - b. 100% ethanol (ETOH): 3 x 10 min.
 - c. Freshly prepared 100% Methanol with 0.3% H₂O₂: 20 min to remove endogenous

- peroxidases (200 ml 100% methanol + 2 ml 30% H₂O₂).
- d. Rehydrate: Soak slide for 1-min intervals with: 95%, 90%, 80%, 70%, 60%, 50%, and 30% ETOH.
 - e. PBS: 3 x 10 min.
3. Block non-specific reactions
 - a. Take out slides from the glass container and absorb excess PBS from slides with a tissue wipe, being careful not to disturb tissue.
 - b. Add 500 µl blocking solution (or according to tissue size) per slide, allowing the solution to cover all tissue.
 - c. Place the slides into slide chamber that has ddH₂O in the bottom for 1-2 h at room temperature.
 4. Primary antibody
 - a. Take out slides from chamber, discard blocking solution and absorb residual solution with a tissue wipe, being careful not to let the tissue dry.
 - b. Add 500 µl primary antibody solution (or according to tissue size) per slide, allow solution to cover all tissue.
 - c. Place the slide into the same slide chamber with ddH₂O at the bottom, cover chamber and incubate at 4 °C overnight.
 5. Secondary antibody
 - a. Fill 3 beakers and the staining jar with PBS.
 - b. Decant primary antibody solution if not recycled. Rinse slide through 3 beakers sequentially, and then place it in staining jar.
 - c. Leave the staining jar at room temperature, changing PBS for at least 5 times, with 10 min intervals. It is optimal to place the staining jar on an orbit shaker that is set at a slow motion (60 rpm).
 - d. Add 500 µl secondary antibody solution (or according to tissue size) per slide to allow solution to cover all tissue.
 - e. Place slides into a slide chamber for 1 h at room temperature.
 6. Tertiary antibody
 - a. Repeat Steps 5a-5c.
 - b. Add 500 µl tertiary antibody solution (or according to tissue size), allow solution to cover all tissue.
 - c. Place slide into slide chamber for 45 min at room temperature.
 - d. Repeat Steps 5a-5c.
 7. DAB reaction
 - a. Decant PBS from staining jar.
 - b. Gently pour DAB solution into the staining jar for exactly 10 min.
 - c. Decant DAB solution into designated waster container. Deactivate DAB solution by adding a small amount of bleach to water container.

- d. Wash slide immediately with H₂O twice to stop color development.
- e. DAB reactive product is brown.
8. Counterstain
 - a. Decant H₂O from staining jar.
 - b. Pour toluidine blue working solution into the jar. When tissues have a blue color as well as brown, stop counterstain by decanting the counterstain solution into a container. It takes 5-10 min.
 - c. Wash slide with H₂O: 3 x 1 min.
 - d. Toluidine blue stains nuclei with blue color.
9. Dehydrate-Xylene-Permount
 - a. Dehydrate slides with ETOHs with 30-second interval, 30%, 50%, 70%, 80%, 90%, 95%, and 100%. Repeat 100% ETOH.
 - b. Immerse with xylene: 2 times.
 - c. Permount.
 - d. Place slide on a flat surface and place in a 40 °C oven until the permount dries.
10. Inspect slide with microscope and record result.

Software

1. ImageJ (<https://imagej.net/Downloads>)

Data analysis

Immunostaining positive cells can be quantitated using free ImageJ. With this protocol, CD8 α -positive cells are primarily found in the interstitium of the kidney. The potential backgrounds and non-specific bindings are minimal. eNOS^{-/-} *db/db* mice spontaneously develop diabetic nephropathy at 8 weeks of age. These mice were treated with erlotinib (an epidermal growth factor tyrosine kinase inhibitor) or vehicle (water) from 8 to 20 weeks of age. Six photos from each mouse are taken, and the average is used as CD8 α -positive cell density from one mouse. The number of CD8 α -positive cells in the kidneys is quantitated from 4 mice from vehicle treated eNOS^{-/-} *db/db* mice and erlotinib treated eNOS^{-/-} *db/db* mice (Figure 1).




Figure 1. Inhibition of EGFR activity with erlotinib decreased renal CD8 α lymphocyte infiltration in eNOS-/- db/db mice. A. The representative pictures of CD8 α staining in the mouse kidneys from eNOS-/- db/db mice with vehicle or erlotinib treatment. B. Quantitative data ($n = 4$, $P < 0.001$). The value are presented as means \pm S.D. The statistical analysis was performed using student's t -test.

Recipes

1. Blocking solution

If the primary antibodies are generated in mouse (mAb), using blocking solution from M.O.M™ Kit (Vector Laboratories, Inc, Burlingame, CA). For primary antibodies generated in non-murine hosts, block the slide with 10% normal serum (in PBS) from host of the secondary antibody. For examples, if the primary antibody is generated in rabbit, and the secondary antibody is generated in goat, then block the slide with 10% normal goat serum diluted in PBS

- Dilute mAb with diluent from M.O.M™ Kit
- Dilute non-mAb primary antibodies in 1% normal serum in PBS from host of the secondary antibody
- Dilute biotinylated goat anti-mouse IgG (H+L) (1:200 dilution) with diluent from M.O.M™ Kit. Dilute all other biotinylated secondary IgG's with PBS (1:200 dilution, Vector Laboratories)
- Prepare tertiary antibody at least 30 min before use and store at room temperature. Add 16 μ l reagent A to 2 ml PBS, mix, and then add 16 μ l reagent B and mix. Depending on the number of slides, prepare an appropriate volume of the solution

2. DAB solution

- Dissolve 60 mg DAB (aliquoted and stored in freezer) in 200 ml of 50 mM Tris-HCl, pH 7.4
- Then add 80 μ l of 30% H₂O₂
- Protect from light

3. Counterstain stock solution

- Add 100 mg toluidine blue to 200 ml 0.1 M phosphate buffer, pH 7.2
- Keep in dark while stirring until completely dissolved. It may take 1-3 days
- Store away from light at room temperature

4. Counterstain working solution

- Filter 30 ml of stock solution using a 10 ml syringe with a 0.2 μ m filter (Tisch Scientific, Millex,

syringe-driven filter unit, 0.22 μ m) into a beaker

- b. Add 170 ml of 0.1 M phosphate buffer, pH 7.2
- c. Store away from light at room temperature

Note: The working solution can be used twice.

Acknowledgments

The authors would like to thank Dr. James McKanna from Vanderbilt University School of Medicine (retired) for his great contribution to this protocol. This work was supported by NIH grants, DK51265, DK95785 and DK62794 (RCH, MZZ), DK103067 (RCH) and the Vanderbilt O'Brien Center (P30DK114809) (RCH, MZZ), VA Merit Award 00507969 (RCH), and the Vanderbilt Center for Kidney Disease. This protocol is derived from previous research papers published in JHC in 1997 (McKanna and Zhang, 1997) and numerous other publications (*e.g.*, Zhang *et al.*, 1997; Zhang *et al.*, 2018).

Competing interests

The corresponding authors declare that there is no conflict of interests.

References

1. Li, Z., Li, Y., Overstreet, J. M., Chung, S., Niu, A., Fan, X., Wang, S., Wang, Y., Zhang, M. Z. and Harris, R. C. (2018). [Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes](#). *Diabetes* 67(9): 1847-1857.
2. McKanna, J. A. and Zhang, M. Z. (1997). [Immunohistochemical localization of lipocortin 1 in rat brain is sensitive to pH, freezing, and dehydration](#). *J Histochem Cytochem* 45(4): 527-538.
3. Zhang, M. Z., Wang, J. L., Cheng, H. F., Harris, R. C. and McKanna, J. A. (1997). [Cyclooxygenase-2 in rat nephron development](#). *Am J Physiol* 273(6): F994-1002.
4. Zhang, M. Z., Wang, S., Wang, Y., Zhang, Y., Ming Hao, C. and Harris, R. C. (2018). [Renal medullary interstitial COX-2 \(Cyclooxygenase-2\) is essential in preventing salt-sensitive hypertension and maintaining renal inner medulla/papilla structural integrity](#). *Hypertension* 72(5): 1172-1179.